Trials of a new asthma drug show that it could prove life changing for many people – who would only need two jabs a year. The ...

The injectable therapy contain antibodies that dampen inflammation in the lungs and is set to revolutionise the way severe ...

An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...

Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...

The parents of a 13-year-old girl who died after an asthma attack led to a cardiac arrest have said they fear "other families will lose children because asthma is too easily dismissed". Emily Albino, ...

Depemokimab has been approved by the MHRA as the first and only biologic with twice-yearly dosing to treat asthma and severe ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

The London-based pharmaceuticals firm explained the approval for Exdensur is as an add-on maintenance treatment of severe asthma "characterised by an eosinophilic phenotype" in both adult and ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

(Alliance News) - GSK PLC on Monday said Exdensur has been approved in the UK, for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps.